Clinical Benefit and Safety of Palbociclib in Hormone Positive Breast Cancer with Visceral Metastasis: Real-World Experience from a Tertiary Cancer Center
Introduction Palbociclib, the first CDK4/6 inhibitor, has shown promising results in phase III clinical studies by enhancing the efficacy of endocrine therapy (ET) in HR +/HER2– advanced breast cancer. However, real-world data on its use in patients with visceral metastatic disease are li...
Guardado en:
| Autores principales: | , , , , |
|---|---|
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
Thieme Medical and Scientific Publishers Pvt. Ltd.
2025-04-01
|
| Colección: | Indian Journal of Medical and Paediatric Oncology |
| Materias: | |
| Acceso en línea: | http://www.thieme-connect.de/DOI/DOI?10.1055/s-0044-1790584 |
| Etiquetas: |
Sin Etiquetas, Sea el primero en etiquetar este registro!
|